{"url_path":"/sec/kytx/8-k/2026-05-12/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1994702/0001193125-26-219377-index.html","accession_number":"0001193125-26-219377","cik":"0001994702","ticker":"KYTX","issuer_name":"Kyverna Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1994702/0001193125-26-219377-index.html","primary_entity_key":"0001994702","primary_entity_name":"Kyverna Therapeutics, Inc."},"word_count":82,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n99.1\n\n \n\n[Press Release issued by Kyverna Therapeutics, Inc. dated May 12, 2026.](kytx-ex99_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nKYVERNA THERAPEUTICS, INC.\n\nDate: May 12, 2026\n\nBy:\n\n/s/ Marc Grasso\n\nMarc Grasso\n\nChief Financial Officer"}